Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

Hepatic fibrosis is a manifestation of different etiologies of liver disease with the involvement of multiple mediators in complex network interactions. Activated hepatic stellate cells (aHSCs) are the central driver of hepatic fibrosis, given their potential to induce connective tissue formation and extracellular matrix (ECM) protein accumulation. Therefore, identifying the cellular and molecular pathways involved in the activation of HSCs is crucial in gaining mechanistic and therapeutic perspectives to more effectively target the disease. In addition to a comprehensive summary of our current understanding of the role of HSCs in liver fibrosis, we also discuss here the proposed therapeutic strategies based on targeting HSCs.

Automated summary

Hepatic fibrosis is a complex manifestation of different liver diseases caused by various factors. Activated hepatic stellate cells (aHSCs) play a central role in the development of hepatic fibrosis by promoting connective tissue formation and extracellular matrix protein accumulation. Understanding the cellular and molecular pathways involved in the activation of HSCs is crucial for developing effective therapeutic strategies. This article provides a comprehensive overview of the role of HSCs in liver fibrosis and discusses potential therapeutic strategies targeting HSCs.